SURFSIDE, FL
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)VANGUARD UROLOGIC RESEARCH FOUNDATION, founded in 2006, is a micro nonprofit that reported $20 in total revenue in fiscal year 2018. Revenue fell 100% from the prior year — a significant decline worth monitoring. Expenses of $28K exceeded revenue, resulting in a 137955% operating deficit.
TO ESTABLISH THE PREMIER TRANSLATION RESEARCH PROGRAM FOCUSED ON PROSTATE DISEASE INCLUDING PROSTATE CANCER AND RELATED DISEASES OF THE AGING PROCESS.
CLINICAL RESEARCH AND COMMUNITY HEALTH PROMOTION OF THE FDA-APPROVED PROSTATE HEALTH INDEX (PHI ) TEST: IN 2012, THE PHI TEST, BASED ON A NOVEL, CLIPPED FORM OF PROSTATE SPECIFIC ANTIGEN (PSA)...
CLINICAL RESEARCH AND COMMUNITY HEALTH PROMOTION OF THE FDA-APPROVED PROSTATE HEALTH INDEX (PHI ) TEST: IN 2012, THE PHI TEST, BASED ON A NOVEL, CLIPPED FORM OF PROSTATE SPECIFIC ANTIGEN (PSA) CO-DISCOVERED BY DR. SLAWIN, WAS FDA-APPROVED TO DETECT PROSTATE CANCER IN MEN WITH A PSA BETWEEN 4 AND 10 NG/ML. IN 2014, THE VANGUARD UROLOGIC INSTITUTE WAS THE FIRST IN THE NATION TO OFFER THE PHI TEST IN THE UNITES STATES. THE PHI TEST ADDRESSES MANY OF THE CONCERNS RAISED BY THE USPSTF REGARDING THE PSA TEST, RAISING THE PROSPECTS OF REDUCING FALSE NEGATIVE TESTS, UNNECESSARY BIOPSIES AND INCREASING THE DETECTION OF HIGH RISK, LIFE-THREATENING PROSTATE CANCER. SINCE THEN VURF HAS BEGUN SEVERAL INITIATIVES INVOLVING THE PHI TEST TO EVALUATE ITS PERFORMANCE AND TO INCREASE AWARENESS AND USE OF THE TEST BY PHYSICIANS AND PATIENTS. VURF VIA ITS CLINICAL DATA AND SPECIMEN BANK IS DEVELOPING A LARGE DATABASE OF PATIENTS WHO HAVE HAD THE TEST DONE, ALONG WITH ANOTHER NOVEL MOLECULAR TEST FOR PROSTATE CANCER SCREENING, THE URINE PCA-3 TEST THE INCLUDES CLINICAL DATA AND PROSTATE BIOPSY RESULTS THAT WILL SERVE AS THE BASIS OF SCIENTIFIC STUDIES OF THE PHI TEST IN CLINICAL PRACTICE . FURTHERMORE, VURF IS DEVELOPING MULTIPLE RESOURCES, INCLUDING MAILING CAMPAIGNS, WEBSITES AND OTHER ACTIVITIES TO HELP EDUCATE PHYSICIANS AND PATIENTS ABOUT THE PHI TEST AND ITS POTENTIAL BENEFITS TO PUBLIC HEALTH.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2018 | 2017 | Change | |
|---|---|---|---|
| Revenue | $20 | $35,015 | -1.0% |
| Expenses | $27,611 | $9,421 | +1.9% |
| Net Income | $-27,591 | $25,594 | -2.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| PHIL WEINSTEIN MD | DIRECTOR | 0.30 |
Director
|
$0 | $0 | $0 |
| KEVIN M SLAWIN MD | PRESIDENT | 8.00 |
Officer
|
$0 | $0 | $0 |
| KEVIN M SLAWIN MD | DIRECTOR | 0.30 |
Officer
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2018 | $20 | $27,611 | No data | $-27,591 |
Compare VANGUARD UROLOGIC RESEARCH FOUNDATION with other nonprofits in Florida and across the country.